Altimmune, Inc. (ALT)
Last updated: 2026-10-21 22:05:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Altimmune, Inc. (ALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.23, with a market capitalization of $433.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.17 to $6.44. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$433.77M | |
$2.31 | |
$44,550.00 | |
$1.51 | |
$2.30 | |
4.15M | |
4.32M | |
-- | |
$6.44 | |
$2.17 | |
-- | |
-- |
Altimmune, Inc. (ALT) After-Hours Stock Price
Altimmune, Inc. (ALT) is trading at $2.22 in after-hours trading as of 2026-10-21 22:01:00, down 3.43% ($0.08) from the regular-session close of $2.30.
After-hours trading shows how investors are pricing ALT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Altimmune, Inc. (ALT) 7-Day Stock Price Change
Over the past seven days, Altimmune, Inc. (ALT) moved from $2.56 to $2.23, representing a decline of 13.09% ($0.33).
The stock traded between $2.17 and $2.63 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.43 million shares, down versus the previous seven-day period, indicating lower trading activity.
ALT 52-Week Price Position
Position in Range: 1.3%
ALT is currently trading at $2.23, placing it 1.3% of the way from its 52-week low of $2.17 to its 52-week high of $6.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Altimmune, Inc. (ALT)?
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Altimmune, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Altimmune, Inc. (ALT) Stock on MEXC
Eligible investors can buy real shares of Altimmune, Inc. (ALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Altimmune, Inc. (ALT) stock price today?
2.Is ALT stock going up or down today?
3.What is ALT pre-market price?
4.What is ALT after-hours price?
5.Is ALT stock trading now?
6.Where does ALT sit relative to its 52-week high and low?
7.What sector is Altimmune, Inc. in?
8.What is Altimmune, Inc.'s market capitalization and where is it listed?
9.How is ALT valued in terms of P/E ratio and EPS?
10.Does Altimmune, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ALT Stock Calculator
Estimate the value between ALT shares and USD.
ALT Shares to USD
1.00 ALT shares = 2.225 USD
Calculations are estimates based on the latest available price and are for reference only.


